Chugai Pharmaceutical Co., Ltd. (CHGCF)
40.74
+0.08
(+0.20%)
USD |
OTCM |
Oct 29, 16:00
Chugai Pharmaceutical Enterprise Value : 61.60B for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | 61.60B |
| October 28, 2026 | 61.47B |
| October 27, 2026 | 72.92B |
| October 26, 2026 | 69.30B |
| October 23, 2026 | 68.31B |
| October 22, 2026 | 64.22B |
| October 21, 2026 | 59.64B |
| October 20, 2026 | 61.70B |
| October 19, 2026 | 62.03B |
| October 16, 2026 | 59.60B |
| October 15, 2026 | 59.66B |
| October 14, 2026 | 54.83B |
| October 13, 2026 | 57.77B |
| October 12, 2026 | 57.16B |
| October 09, 2026 | 56.58B |
| October 08, 2026 | 55.74B |
| October 07, 2026 | 57.52B |
| October 06, 2026 | 58.18B |
| October 05, 2026 | 59.21B |
| October 02, 2026 | 57.53B |
| October 01, 2026 | 56.83B |
| September 30, 2026 | 61.29B |
| September 29, 2026 | 59.32B |
| September 28, 2026 | 60.74B |
| September 25, 2026 | 62.49B |
| Date | Value |
|---|---|
| September 24, 2026 | 61.31B |
| September 23, 2026 | 64.23B |
| September 22, 2026 | 65.29B |
| September 21, 2026 | 65.51B |
| September 18, 2026 | 62.65B |
| September 17, 2026 | 64.23B |
| September 16, 2026 | 52.21B |
| September 15, 2026 | 61.94B |
| September 14, 2026 | 65.33B |
| September 11, 2026 | 64.53B |
| September 10, 2026 | 59.76B |
| September 09, 2026 | 62.26B |
| September 08, 2026 | 66.14B |
| September 04, 2026 | 65.49B |
| September 03, 2026 | 66.58B |
| September 02, 2026 | 62.63B |
| September 01, 2026 | 62.31B |
| August 31, 2026 | 67.01B |
| August 28, 2026 | 67.25B |
| August 27, 2026 | 66.22B |
| August 26, 2026 | 64.74B |
| August 25, 2026 | 63.96B |
| August 24, 2026 | 68.04B |
| August 21, 2026 | 63.34B |
| August 20, 2026 | 65.08B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co., Ltd. | 90.39B |
| Daiichi Sankyo Co., Ltd. | 29.30B |
| Eisai Co., Ltd. | 8.784B |
| Santen Pharmaceutical Co., Ltd. | 3.166B |
| Ono Pharmaceutical Co., Ltd. | 5.667B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 901.42M |
| Revenue (Quarterly) | 2.542B |
| Total Expenses (Quarterly) | 1.640B |
| EPS Diluted (Quarterly) | 0.5479 |
| Gross Profit Margin (Quarterly) | 70.58% |
| Profit Margin (Quarterly) | 35.47% |
| Earnings Yield | 4.77% |
| Operating Earnings Yield | 6.67% |
| Normalized Earnings Yield | 4.858 |